VEGF-Trap: A VEGF blocker with potent antitumor effects

By J. Holash, S. Davis, N. Papadopoulos, S. Croll, L. Ho, M. Russell, P. Boland, Raymond Leidich, D. Hylton, E. Burova and 9 more. Proceedings of the National Academy of Sciences of the United States of America, 2002

1,717 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/d0f356f173df69543416922817109273247126da

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. N. Ferrara
2. A. Adamis
3. H. Gerber
4. D. McDonald
5. W. Novotny
6. Kenneth J. Hillan
7. Rakesh K. Jain
8. P. Baluk

In Oncology

1. N. Ferrara
2. A. Adamis
3. D. McDonald
4. H. Gerber
5. Kenneth J. Hillan
6. H. Hashizume
7. P. Baluk
8. W. Novotny

In Radiology, Nuclear Medicine and Imaging

1. N. Ferrara
2. A. Adamis
3. David M. Brown

Citations in the corpus

• Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. (2014, positive): “As a designed molecule featuring optimal pharmacologic characteristics to inhibit intraocular VEGF, intravitreal aflibercept injection offers improved binding affinity and superior pharmacokinetics in an iso-osmotic formulation.(14,15) The VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet A”
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Aflibercept inhibits the binding and activation of the VEGF family and natural VEGFR by specifically blocking VEGF-A and most proangiogenic cytokines, thereby inhibiting division and proliferation of ECs, reducing vascular permeability, and is commonly used in non-neoplastic angiogenic disease like ”
• Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex (2010, methodology): “For instance, the currently used VEGF-trap is a combination of the VEGFR1D2 and VEGFR2-D3 domains (28).”
• Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. (2004, background): “Both agents were selected because they are potent inhibitors of VEGF signaling and have documented efficacy in preclinical tumor models.(21,27,31,35) Although the main focus of the present studies was to analyze direct effects on tumor vessels during the first week, prolongation of treatment to 3 we”
• VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. (2004, methodology): “When added to tissue cultures at approximately equimolar concentrations, VEGF TrapR1R2 has been shown to block VEGF-A–induced phosphorylation of VEGFR2 as well as proliferation of primary human umbilical vein endothelial cells (24).”